Perrigo (PRGO) Depreciation & Amortization (CF) (2013 - 2026)
Perrigo (PRGO) reported Depreciation & Amortization (CF) of $83.3 million for Q1 2026, up 4.26% year-over-year from $79.9 million in Q1 2025, and down 3.03% quarter-over-quarter from $85.9 million in Q4 2025.
Perrigo (PRGO) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $83.3 million in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $83.3 million, up 4.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $340.9 million (up 5.09% YoY), and the FY2025 annual result was $337.5 million, up 3.56% from the prior year.
- Depreciation & Amortization (CF) fell to $83.3 million in Q1 2026 per PRGO's latest filing, from $85.9 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $97.1 million in Q4 2022 and troughed at $69.5 million in Q2 2022.
- A 5-year average of $85.0 million and a median of $85.4 million in 2025 frame the typical range for Depreciation & Amortization (CF).
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 32.29% in 2022 and fell as far as 23.12% in 2022.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $97.1 million in 2022, then retreated by 11.53% to $85.9 million in 2023, then retreated by 6.52% to $80.3 million in 2024, then climbed by 6.97% to $85.9 million in 2025, then fell by 3.03% to $83.3 million in 2026.
- Business Quant data shows PRGO's Depreciation & Amortization (CF) at $83.3 million in Q1 2026, $85.9 million in Q4 2025, and $85.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn | 83.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 83.30 Mn |
| Mar 28, 2026 | 83.30 Mn |
| Dec 31, 2025 | 85.90 Mn |
| Dec 31, 2025 | 85.90 Mn |
| Sep 27, 2025 | 85.40 Mn |
| Sep 27, 2025 | 85.40 Mn |
| Jun 28, 2025 | 86.30 Mn |
| Jun 28, 2025 | 86.30 Mn |
| Mar 29, 2025 | 79.90 Mn |
| Mar 29, 2025 | 79.90 Mn |
| Dec 31, 2024 | 80.30 Mn |
| Dec 31, 2024 | 80.30 Mn |
| Sep 28, 2024 | 82.30 Mn |
| Sep 28, 2024 | 82.30 Mn |
| Jun 29, 2024 | 81.90 Mn |
| Jun 29, 2024 | 81.90 Mn |
| Mar 30, 2024 | 81.40 Mn |
| Mar 30, 2024 | 81.40 Mn |
| Dec 31, 2023 | 85.90 Mn |
| Dec 31, 2023 | 85.90 Mn |